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Abstract Öz 
Purpose: Nitric oxide is an important mediator that plays 
a major role in platelet adhesion/aggregation. Asymmetric 
dimethylarginine (ADMA) is a competitive inhibitor of 
endothelial nitric oxide synthase. In this study, we aimed 
to examine the ADMA levels in diagnosis and follow-up 
of acute pulmonary thromboembolism. 
Materials and Methods: The study was designed as a 
prospective study. Thirty consecutive patients with acute 
PTE and 20 healthy volunteers were enrolled into the 
study. Patients were followed 1 month. Plasma ADMA 
levels were measured on  admission and following the first 
month. 
Results: Ona dmision there was statistically significant 
difference between two groups. When we compared 
serum ADMA levels difference between patients group 
with resolution and without resolution, there was not any 
statistically significant difference. There was a significant 
difference between serum ADMA levels of massive group 
and the other 2 groups. 
Conclusion: Plasma ADMA levels elevated in patients 
with pulmonary thromboembolism. This finding supports 
the idea ADMA levels correlated with thrombus burden. 
Amaç: Nitrik oksit trombosit yapışması ve toplanmasında 
rol oynayan önemli bir maddedir. Asimetrik dimetilarjinin 
(ADMA) endotelyal nitrik oksit sentetazın yarışmacı 
inhibitörüdür ve seviyesi hipokside artar. Bu çalışmada 
ADMA seviyesin akut pulmoner tromboembolizm tanı ve 
takibindeki yerini araştırmayı amaçladık. 
Gereç ve Yöntem: Çalışma prospektif olarak dizayn 
edildi. Akut pulmoner tromboembolizmi olan 30 hasta ve 
20 sağlıklı gönüllü çalışmaya dahil edildi. Hastalar 1 ay 
takip edildi. Plazma ADMA seviyesi başvuruda ve 1. ay 
takipte ölçüldü. 
Bulgular: Hastaneye başvuru sırasındaki hasta ve kontrol 
grubunun serum ADMA seviyeleri arasında istatistiksel 
anlamlı fark vardı. Birinci ay kontrolde rezolüsyonu olan 
ve olmayan grupların serum ADMA değişimi arasında 
istatistiksel anlamlı fark bulunmadı. Serum ADMA seviyesi 
masif olan grupta, submasif ve masif olmayan gruplara 
göre daha yüksekti.  
Sonuç: Plazma ADMA seviyesi akut pulmoner 
tromboembolizmi olan hastalarda yükselir ve ADMA 
seviyesi trombüs yükü ile koreledir. 
Key words: Pulmonary embolism, asymmetric 
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INTRODUCTION 
Pulmonary artery embolism is defined as a partial or 
complete occlusion of a pulmonary arterial branch. 
It is associated with high morbidity and mortality, 
which may sometimes be difficult to diagnose. 
Approximately 70-90% of cases are caused by 
thrombosis of lower extremity veins1-2. Venous 
thromboembolism (VTE) encompasses deep vein 
thrombosis (DVT) and pulmonary 
thromboembolism (PTE). It is the third most 
frequent type of cardiovascular disease3-4. 
Hypercoagulability, endothelial damage and stasis 
are known to play role in pathophysiology of PTE5-
6. The main mechanism of nitric oxide (NO) 
involves that inhibition of proliferation of smooth 
Cilt/Volume 43 Yıl/Year 2018       Asymmetric dimethylarginine, pulmonary embolism 
 
 445 
muscle cells, endothelium derived vasodilatation, 
cell-cell interaction in blood vessels (platelet 
adhesion/aggregation and inhibition of monocyte 
adhesion) so NO plays a key role in PTE 
pathophysiology7-10. Asymmetric dimethylarginine 
(ADMA) is competitive inhibitor of endothelial 
nitric oxide synthase (e-NOS) so plays a regulatory 
role in the formation of endothelial NO11-14. Plasma 
ADMA levels increases in hypoxia10. In this study, 
we aimed to examine the plasma ADMA levels in 
diagnosis and follow-up of acute PTE. 
MATERIALS AND METHODS 
Thirty consecutive patients admitted to hospital on 
an outpatient basis between December 2009 and 
October 2010 were evaluated for possible 
enrollment into the study. This prospective study 
was approved by the local ethics committee 
(KA09/276). Each patient provided a signed 
informed consent form. 
The following were excluded from the study: 
patients with known malignancy, liver disease, active 
infection, diabetes mellitus, congestive heart failure 
and patients, who did not want to join the study. 
Twenty healthy volunteers were taken in our study. 
Patients were followed 1 month. Plasma ADMA 
levels were measured on admission and first month. 
Computed tomographic angiography (CTPA) and 
echocardiography were performed in patients on 
admission and the end of first month. Status of 
hypoxemia was evaluated with arterial blood gas on 
admission. It was evaluated with arterial blood gas 
or pulse oxymetri at the end of first month. The 
diagnosis of PTE was confirmed only when CTPA 
showed a pulmonary vascular filling defect. 
Patients received either low- molecular-weight 
heparin at a fixed dose per kilogram of body weight 
subcutaneously two times per day or unfractionated 
heparin at an initial bolus dose of 80IU per kilogram 
followed by a continuous intravenous infusion at an 
initial rate of 18 IU per kilogram per hour. The dose 
was subsequently adjusted so  that the activated 
partial thromboplastin time (aPTT) was two to three 
times the control value in normal subjects. In each 
patient, oral anticoagulant therapy (warfarin) was 
initiated at first day of heparin and continued 
together for 3 days. Patients were treated for three 
months with warfarin. The dose was adjusted to 
achieve an international normalized ratio (INR) of 
2.0 to 3.0. 
Biochemical analysis 
Plasma ADMA levels were analyzed by using high 
performance liquid chromatography (HPLC). The 
method includes reversed phase HPLC analysis by 
using fluorescence detection (Shimadzu LC 10A 
fluorescent detector, Japan) in a high-performance 
liquid chromatography system (Shimadzu RF 10XL, 
Japan). The plasma concentrations of ADMA were 
measured by HPLC with precolumn derivatization 
with ophthaldialdehyde (OPA) and 3-
mercaptopropionic acid. Samples and standards 
were incubated with OPA reagent for exactly 30 s 
before injection into the HPLC system15. 
Statistical analysis 
Variables are presented as mean±SD or median 
(range, interquartile range [IQR]) for continuous 
data and as proportion for categorical data. The 
compliance of numerical variables to a normal 
distribution was assessed using the Shapiro Wilk 
test. Relationships between categorical variables 
were assessed by the Chi- Square and Fisher’s exact 
tests. Non parametric data were compared with the 
Mann-Whitney U or Kruskall-Walls analyze test as 
appropriate. Comparisons of pre and post treatment 
values were performed using the Wilcoxon test. 
Linear relationships between two variables were 
assessed using the Pearson (for parametric data) and 
Spearman (for non parametric data) correlation 
analyses. Results were evaluated using 95% 
confidence intervals, and p<0.05 was considered 
statistically significant. Statistical analysis was 
performed using commercially available computer 
program (SPSS version 21.0 for Windows; SPSS, 
Inc., Chicago, Illinois, US). 
RESULTS 
A total of 50 participants (30 patients and 20 
controls) were enrolled into the study. In the 
patients group mean age was 64.9±16.5 years and 22 
(73.60%) patients were women. In the control group 
mean age was 64.1±14.3 years and 14 (70%) patients 
were women. There was no significant difference 
between baseline demographic characteristics 
between the two groups (p>0.05). Baseline clinic 
characterics of study patients on admission are 
summarized in table 1. There was a statistically 
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significant difference between patient and control 
group according to serum ADMA levels. In the 
patients groups serum ADMA levels was 0,35 (0.16-
0.62; IQR: 0.46) μmol/L and in the control group 
serum ADMA levels was 0.18 (0.11-0.29; IQR: 0.18) 
μmol/L (p=0.022). Comparison of serum ADMA 
levels on admission are shown in Figure 1. Twenty 
three patients had thrombus resolution but 7 
patients had not thrombus resolution in first month 
control. When we compared serum ADMA levels 
difference (ΔADMA) between admission and at the 
end of firsth month control in patients group with 
resolution (n:23) and without resolution (n:7) found 
there was not a different (respectively, ΔADMA was 
-0.07 (-0.33-0.09; IQR: 0.42) μmol/L and -0.12 (-
0.27- 0.29; IQR: 0.56) μmol/L p=0.666). 
Comparison of ΔADMA between the groups are 
shown in Figure 2. When we compared serum 
ADMA levels in massive, submassive and non 
massive groups, there was a significant difference 
between serum ADMA levels of massive group and 
the other 2 groups (massive group ADMA levels 
was 1.4 (1.3-1.59; IQR: 0.29, submassive group 
ADMA levels was 0.31 (0.17-0.57; IQR:0.4), 
nonmassive group ADMA levels 0.27 (0.14-0.52; 
IQR: 0.38) μmol/L (p=0.019). There was no 
difference between non massive and submassive 
groups (p=1). Comparison of serum ADMA levels 
on admission between PTE degree groups are 
shown in Figure 3. We found positive correlation 
between serum ADMA levels on admission with 
systolic pulmonary arterial pressure (sPAP) and right 
ventricle (RV) systolic function (respectively 
p=0.002, r=0.53 and p=0.012, r=0.45). Conversely 
there was a negative correlation between serum 
ADMA levels on admission and partial oxygen 
pressure (PaO2) (p=0.021, r= -0.42). We showed 
that there was a correlation between ADMA levels 
and sPAP (Figure 4) and ADMA levels and PaO2 
(Figure-5). 
Tablo 1. Baseline clinical characterics of the study patients on admission. 
Clinical characterics PTE group (n=30) 
sPAP, mm Hg, mean±SD 40.1±16.2 
PaO2, mm Hg, mean±SD 71.6±17.6 
D-dimer, ug/ml, mean±SD 2.2±1.7 
PTE degree  
Non massive 13 (43.3%) 
Submassive 14 (46.7%) 
Massive 3 (10%) 
RV systolic function  
Normal 13 (46%) 
Slightly depressed 12 (40%) 
Moderate depressed 4 (13%) 
Severe depressed 1 (3.3%) 
PAP: Pulmonary arterial pressure, PaO2: Partial oxygen pressure, PTE: Pulmonary thromboembolism, RV: Right ventricle 
 
 
 
Figure-1. Comparison of serum ADMA levels on 
admission patient and control groups (p=0.022). 
Figure 2. Comparison of serum ADMA levels change 
(ΔADMA) between admission and first month 
control in patient group with resolution and without 
resolution (p=0.666). 
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Figure 3. Comparison of serum ADMA levels on 
admission between PTE degree groups (p=0.019). 
Figure 4. Correlation between serum ADMA levels 
and sPAP (p=0.002, r=0.53). 
 
 
Figure 5. Correlation between serum ADMA levels 
and sPaO2 (p=0.021, r = - 0.42). 
DISCUSSION 
PTE is a disease associated with high morbidity and 
mortality, which may sometimes be difficult to 
diagnose. Hypoxia, pulmonary hypertension, and 
RV systolic dysfunction are well-known risk factors 
for increased morbidity and mortality16. Ninety 
percent of PTEs arise from proximal deep veins of 
lower extremity, and more than 50% of proximal 
DVTs result in PTE5. Factors responsible for 
intravascular coagulation were first described by 
Virchow in 1856. Endothelial dysfunction, 
hypercoagulopathy, and stasis are the risk factors for 
intravascular coagulation17. Dysfunction of injured 
endothelium results in a reduced NO synthesis, 
decreasing the protective effect of NO8. NO is 
constantly released under normal conditions; various 
substances (acetylcholine, noradrenaline, ATP, 
bradykinin etc.) and pharmacological agents (L-
arginine) increase NO synthesis by stimulating the 
activity of the e-NOS enzyme8. Dysfunctional 
endothelial L-arginine/NO pathway constitutes the 
main mechanism for the detrimental effects of many 
cardiovascular risk factors (hypercholesterolemia, 
hypertension, smoking, diabetes mellitus, vascular 
inflammation etc.) on vessel wall9. In 1992 the 
discovery of ADMA as the endogenous competitive 
inhibitor of NOS suggested that this molecule may 
have a role in the dysfunction of the endothelial L-
arginine/NO pathway10. ADMA reduces NO 
production and its protective bioactivity in a dose-
dependent manner. In addition, high ADMA levels 
leads to production of detrimental superoxide 
radicals instead of NO by eNOS. As a result, 
ADMA affects the hemostatic balance between 
vasodilation and vasoconstriction, thrombocyte 
activation, cell-to-cell interaction, pro-
/antiproliferative balance, pro-/antioxidative 
stimulation, and pro-inflammatory process11. Lungs 
are the primary source of NOS and ADMA and 
they acts as the primary organs that are responsible 
for the balance between NOS and ADMA18. 
ADMA is metabolized by dimethyl arginine 
dimethyl amino hydrolase (DDAH) and its isoform 
DDAH II19. It has been reported that DDAH II 
activity is reduced in hypoxia-induced pulmonary 
hypertension20. Suppressed endothelial DDAH II 
activity is considered a major cause of pulmonary 
hypertension21. Many studies to date have 
demonstrated that lower DDAH I activity is another 
factor for increased ADMA and decreased NO 
levels21-22. It is known that ADMA levels elevate in 
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pulmonary hypertension associated with congenital 
heart defects and in idiopathic pulmonary 
hypertension13;23. All these information suggest that 
hypoxia is the main culprit for elevated ADMA 
levels in PTE. 
Dominik G et al. did not find any significant 
differences between plasma ADMA, L- arginine, 
and symmetric dimethylarginine levels in patients 
with DVT and control subjects24. In that study, 
however, none of the patients had PTE or 
hypoxemia. In our study ADMA levels were 
significantly higher in patients with PTE compared 
to the control subjects, suggesting that ADMA may 
be an ancillary marker for the diagnosis of PTE. 
Considering the Virchow triad, it is clear that 
patients with DVT also has endothelial dysfunction 
and hypercoagulability. Thrombus in the pulmonary 
arteries may have led to a higher ADMA levels as a 
result of hypoxia with hypoxia-induced endothelial 
injury and increased oxygen radicals. In our study 
there was a negative correlation between ADMA 
levels and PaO2. 
The lack of any significant difference between 
patients with and without resolution with respect to 
the change in ADMA (ΔADMA) levels may be 
explained by an improvement of hypoxemia also in 
patients without resolution. These findings may 
suggest that hypoxemia may be the cause of a higher 
ADMA levels in PTE. We found a negative 
correlation between ADMA levels and PaO2 levels 
on arterial blood gas analysis. These findings may 
support the hypothesis that hypoxia is the primary 
mediator of ADMA elevation. 
Skoro-Sajer et al. showed that plasma ADMA levels 
increased in patients with chronic thromboembolic 
pulmonary hypertension (CTEPH)12. They showed 
that hemodynamic parameters and the severity of 
pulmonary vascular disease were significantly 
correlated to plasma ADMA levels12. The authors 
also suggested that ADMA was a predictor of 
mortality and morbidity in patients with CTEPH12. 
Another study showed elevated ADMA levels in 
PTE, although it was not a predictor of CTEPH 
development25. That study, however, also included 
patients with chronic disease. 
There are some limitations of this study. At the 
control visit first month later hypoxemia was 
checked with a pulse oximetry, and no arterial blood 
gas analysis was done when oxygen saturation 
exceeded 92%. Hence, not all patients underwent 
arterial blood gas analysis at the first month visit. In 
our study, one of the possible mechanisms was 
hypoxia-induced endothelial injury that is further 
exacerbated by oxygen radicals, impairing NO 
metabolism. However, no parameter was evaluated 
to measure the amount of oxygen radicals. Massive 
PTE was diagnosed in only 3 of 30 patients in the 
PTE group. Therefore, one other limitation of this 
study is a number of patients as low as 3 in this 
group where ADMA’s effects may have been 
greatest. This study enrolled a total of 30 patients 
who are not representative of a general patient 
population. Therefore, we suggest that more studies 
with a larger sample size should be conducted in this 
field. Furthermore, the study is not a long term 
follow up design, like third or sixth month. 
In conclusion, plasma ADMA levels were found 
elevated in PTE, and ADMA levels were correlated 
to thrombus burden. ADMA elevation in acute PTE 
probably occurs through hypoxia-induced 
mechanisms. Plasma ADMA levels, in addition to 
biochemical and imaging tests, may be helpful in 
determination of the severity of PTE. However, 
plasma ADMA levels may not be a useful parameter 
in the follow-up of PTE and assessment of 
thrombus resolution at the first month of therapy. 
REFERENCES 
1. Agnelli G, Becattini C. Acute pulmonary embolism. 
N Engl J Med. 2010;363:266-74. 
2. Konstantinides SV, Torbicki A, Agnelli G, Danchin 
N, Fitzmaurice D, Galiè N et al. Task Force for the 
Diagnosis and Management of Acute Pulmonary 
Embolism of the European Society of Cardiology 
(ESC). 2014 ESC guidelines on the diagnosis and 
management of acute pulmonary embolism. Eur 
Heart J. 2014;35:3033-69. 
3. Heit JA. The epidemiology of venous 
thromboembolism in the community. Arterioscler 
Thromb Vasc Biol. 2008;28:370–2. 
4. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, 
Bergqvist D, Brecht JG et al. Venous 
thromboembolism (VTE) in Europe. The number of 
VTE events and associated morbidity and mortality. 
Thromb Haemost. 2007;98:756-64. 
5. Girard P, Sanchez O, Leroyer C, Musset D, Meyer 
G, Stern JB et al. Deep venous thrombosis in 
patients with acute pulmonary embolism: prevalence, 
risk factors, and clinical significance. Chest. 
2005;128:1593-600. 
6. Riedel M. Acute pulmonary embolism 1: 
Pathophysiology, clinical presentation, and diagnosis. 
Heart. 2001;85:229-40. 
Cilt/Volume 43 Yıl/Year 2018       Asymmetric dimethylarginine, pulmonary embolism 
 
 449 
7. Furchgott RF, The Discovery of endothelium 
derived relaxing factor and its importance in the 
identification of nitric oxide. J Am Med Assn. 
1996;276:1186-8. 
8. Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, 
Bhagat K, Taylor M et al. Acute systemic 
inflammation impairs endothelium-dependent 
dilatation in humans. Circulation. 2000;102:994-9. 
9. Sydow K, Munzel T. ADMA and oxidative stress. 
Atherosclerosis suppl. 2003;4:41-51. 
10. Skoro-Sajer N, Mittermayer F, Panzenboeck A, 
Bonderman D, Sadushi R, Hitsch R et al. 
Asymmetric dimethylarginine is increased in chronic 
thromboembolic pulmonary hypertension. Am J 
Respir Crit Care Med. 2007;176:1154-60. 
11. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, 
Chan JR, Tangphao O et al. Asymmetric 
dimethylarginine (ADMA): a novel risk factor for 
endothelial dysfunction: its role in 
hypercholesterolemia. Circulation. 1998;98:1842-7. 
12. Vallance P, Leone A, Calver A, Collier J, Moncada S. 
Accumulation of an endogenous inhibitor of NO 
synthesis in chronic renal failure. Lancet. 
1992;339:572-5. 
13. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, 
Tsikas D, Frolich JC et al. Cardiovascular effects of 
systemic nitric oxide synthase inhibition with 
asymmetrical dimethyl argininein humans. 
Circulation. 2004;109:172-7. 
14. Milat LJ, Whitley J, Leiper JM, Jeimes LD, Siragy 
MH, Carey RM et al. Evidence for Dysregulation of 
Dimethyl arginine Dimethyl aminohydrolase I in 
Chronic Hypoxia induced Pulmonary Hypertension. 
Circulation. 2003;108:1493-98. 
15. Teerlink T. HPLC analysis of ADMA and other 
methylated L-arginine analogs in biological fluids. J 
Chromatogr B Analyt Technol Biomed Life Sci. 
2007;851:21-9. 
16. James E. Dalen. Pulmonary embolism: What have 
we learned since Virchow? natural history, 
pathophysiology, and diagnosis. Chest. 
2002;122:1440-56. 
17. White RH. The epidemiology of venous 
thromboembolism. Circulation. 2003;107:14-8. 
18. Bulau P, Zakrzewicz D, Kitowska K, Leiper J, 
Gunther A, Grimminger F et al. Analysis of 
methylarginine metabolism in the cardiovascular 
system identifies the lung as a major source of 
ADMA. Am J Physiol Lung Cell Mol Physiol. 
2006;292:18-24. 
19. Arrigoni FI, Vallance P, Haworth SG, Leiper JM. 
Metabolism of asymmetric dimethylarginines is 
regulated in the lung developmentally and with 
pulmonary hypertension induced by hypobaric 
hypoxia. Circulation. 2003;107:1195–201. 
20. Pullamsetti S, Kiss L, Ghofrani HA, Voswinckel R, 
Haredza P, Klepetko W et al. Increased levels and 
reduced catabolism of asymmetric and symmetric 
dimethylarginines in pulmonary hypertension. 
FASEB J. 2005;19:1175-7. 
21. Sasaki A, Doi S, Mizutani S, Azuma H. Roles of 
accumulated endogenous nitric oxide synthase 
inhibitors, enhanced arginase activity, and attenuated 
nitric oxide synthase activity in endothelial cells for 
pulmonary hypertension in rats. Am J Physiol Lung 
Cell Mol Physiol. 2007;292:1480-7. 
22. Leiper J, Nandi M, Torondel B, Murray-Rust J, 
Malaki M, O’Hara B et al. Disruption of 
methylarginine metabolism impairs vascular 
homeostasis. Nat Med. 2007;13:198-203. 
23. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer 
HE. Plasma levels of asymmetrical dimethyl-L-
arginine in patients with congenital heart disease and 
pulmonary hypertension. J Cardiovasc Pharmacol. 
2001;37:489-92. 
24. Haider DG, Bucek RA, Reiter M, Minar E, Hron G, 
Kyrle PA et al. The cardiovascular risk marker 
asymmetrical dimethylarginine is not affected by 
venous thromboembolism. Transl Res.  2006;148:26-
9. 
25. Altuntaş M, Atalay F, Can M, Altın R, Tor M. Serum 
asymmetric dimethylarginine, nitrate, vitamin B(12), 
and homocysteine levels in individuals with 
pulmonary embolism. Mediators Inflamm. 
2011;2011:215057. 
 
 
